Background With the development of modern therapies, better care of patients with primary Sjogren's syndrome has been achieved. However, primary Sjogren's syndrome may share an association with risk of lymphoproliferative disease or other malignancy.
Objectives To investigate the clinical features of primary Sjogren's syndrome (pSS) patients with malignancies.
Methods We studied clinical features of the pSS patients coexist with malignancies in the Third Affiliated hospital of Sun Yat-sen University from 2002 to 2015. Thirteen out of 918 patients with pSS developed malignancies, both solid tumors and lymphomas. Student's t test was used to compare patients'age and age of onset.
Results The ratio of pSS with malignancies was 1.4% (13/918) in these patients. 6 were lymphoma, including 5 diffuse large B-cell lymphoma (DLBCL) and one mucosa associated lymphoid tissue type (MALT) Lymphoma. 7 were solid tumors, including one Colon cancer, one Hepatocellular carcinoma, one cervical carcinoma, one ovarian cancer, and one breast cancer, one cervical lymph nodes of squamous cell carcinoma and one peritoneal metastasis of unknown origin. The onset age of pSS was 44.5±19years,and onset age of malignancies was 47±18.4years. it seems that the age of pSS patients with solid tumors (53.6±18.9 years) was older than the age of pSS patients with lymphoma (34±13.9 years),but there was no significant difference.
Conclusions The most frequent cancer associated with pSS is Lymphomas. the age of pSS patients with solid tumors might be older than the age of pSS patients with lymphoma.
Theander, E.; Henriksson, G.; Ljungberg, O.; Mandl, T.; Manthorpe, R.; Jacobsson, L. T., Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Annals of the rheumatic diseases 2006, 65 (6), 796–803.
Boussios, S.; Pentheroudakis, G.; Somarakis, G.; Markatseli, T. E.; Drosos, A. A.; Pavlidis, N., Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature. Anticancer research 2014, 34 (11), 6669–76.
Disclosure of Interest None declared